Triple Immunotherapy Combo for Recurrent SCLC Terminated After Enrolling 9 Patients

Small cell lung cancer is among the deadliest thoracic malignancies, with a five-year survival rate below 7%. After progression on platinum-based chemotherapy — the standard first-line treatment — patients have extremely limited options and poor prognosis. Finding effective second-line therapies remains one of oncology's most urgent unmet needs.

This phase I/II single-arm trial, sponsored by H. Lee Moffitt Cancer Center, sought to evaluate the combination of nivolumab, ipilimumab, and lurbinectedin in patients with relapsed or recurrent SCLC. Nivolumab and ipilimumab are dual immune checkpoint inhibitors targeting PD-1 and CTLA-4, respectively, and have shown activity in other solid tumors. Lurbinectedin, an RNA polymerase II inhibitor, received accelerated FDA approval in 2020 for SCLC monotherapy. The scientific rationale for combining these agents was that lurbinectedin's immunomodulatory properties might synergize with checkpoint blockade to enhance anti-tumor immunity.

The trial's primary objectives were to determine the maximum tolerated dose and recommended phase II dose of the combination, along with characterizing its safety and early efficacy signals. Unfortunately, the study was terminated before meaningful data accrual, with only 9 patients enrolled from its November 2020 start through its March 2024 completion date.

The early termination is clinically significant. In relapsed SCLC, where every new therapeutic avenue matters, a terminated trial leaves unanswered questions about whether this triple combination could have offered meaningful benefit. Termination may reflect toxicity signals, poor accrual, or external factors such as competing trials or changes in the treatment landscape.

For clinicians, the lesson is cautious optimism about combining lurbinectedin with checkpoint inhibitors — the mechanistic rationale remains sound, but safety and tolerability in this heavily pretreated population require careful evaluation. Future trials exploring this combination should incorporate robust dose-escalation designs and vigilant toxicity monitoring.